Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
Gliomas have a dismal prognosis, with the median survival of patients with the most common histology, glioblastoma multiforme, being only 12-15 months. Development of novel therapeutic agents is urgently needed. We have previously demonstrated that oncolytic measles virus strains derived from the Edmonston vaccine lineage have significant antitumor activity against gliomas [Phuong, L.K., Allen, C., Peng, K.W., Giannini, C., Greiner, S., Teneyck, C.J., Mishra, P.K., Macura, S.I., Russell, S.J., Galanis, E.C. (2003). Cancer. Res. 63, 2462-2469]. MV-CEA is an Edmonston vaccine lineage measles virus strain engineered to express the marker peptide carcinoembryonic antigen (CEA): CEA levels can serve as a correlate of viral gene expression. In support of a phase I clinical trial of intratumoral and resection cavity administration of MV-CEA to patients with recurrent gliomas, we assessed the neurotoxicity of MV-CEA in adult immune male rhesus macaques (Macaca mulatta). The animals ' immune status and administration schedule mimicked the trial population and proposed administration schema. Macaca mulatta represents the prototype animal species for assessment of measles neurotoxicity. The animals were stereotactically administered either vehicle (n = 1) or MV-CEA at 2 x 10(5)or 2 x 10(6) TCID(50) (each, n = 2) in the right frontal lobe in two injections on days 1 and 5. Macaques were closely monitored clinically for neurotoxicity. Body weight, temperature, complete blood count, CEA, clinical chemistries, coagulation, complement levels, immunoglobulin, measles antibody titers, viremia, and shedding (buccal swabs) were tested at multiple time points. Furthermore, cisterna magna spinal taps were performed on day 9 and 1 year after the first viral dose administration, and samples were analyzed for protein, glucose, cell differential, and presence of MV-CEA. Magnetic resonance imaging (MRI) was performed between 4 and 5 months after article administration to assess for subclinical neurotoxicity. To date, 36+ months from study initiation there has been no clinical or biochemical evidence of toxicity, including lack of neurological symptoms, fever, or other systemic symptoms and lack of immunosuppression. Quantitative RT-PCR analysis of blood, buccal swabs, and cerebrospinal fluid (CSF) was negative for MV-CEA at all time points, with the exception of viral genome deletion in the blood of one asymptomatic animal at the 2 x 10(6) TCID(50) dose level on day 85. Vero cell overlays of CSF cells and supernatant were negative for viral recovery. There was no detection of CEA in serum or CSF at any time point. MRI scans were negative for imaging abnormalities and showed no evidence of encephalitis. Our results support the safety of CNS administration of MV-CEA in glioma patients. A clinical trial of intratumoral and resection cavity administration of MV-CEA in patients with recurrent glioblastoma multiforme is currently ongoing.
Myers
Rae
R
Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA.
Harvey
Mary
M
Kaufmann
Timothy J
TJ
Greiner
Suzanne M
SM
Krempski
James W
JW
Raffel
Corey
C
Shelton
Steven E
SE
Soeffker
Diane
D
Zollman
Paula
P
Federspiel
Mark J
MJ
Blanco
Michael
M
Galanis
Evanthia
E
D000818:Animals; D001921:Brain / Q000821:virology; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000378:metabolism*; D002522:Chlorocebus aethiops; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003588:Cytopathogenic Effect, Viral; D004333:Drug Administration Routes; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects; D005910:Glioma / Q000235:genetics / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D008459:Measles virus / Q000235:genetics / Q000472:pathogenicity; D012008:Recurrence; D016896:Treatment Outcome; D014709:Vero Cells
D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen